Johnson & Johnson (JNJ) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Johnson & Johnson offers robust near-term return potential backed by strong Q4 2025 results, significant FDA approvals and pipeline catalysts, plus positive short-term technical momentum supporting a bullish outlook into early 2026.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High Margins ⢠Solid Cash Flow ⢠Thin Liquidity JNJ remains fundamentally strong with high profitability and solid full-year cash generation, but modest liquidity, meaningful leverage, and a premium valuation limit near-term upside.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support holding ⢠Weak rebound Support Level: $226 Resistance Level: $234â$240 JNJ has drifted lower over the last month, making lower highs/lows and staying capped by $234â$240, while $226 support is still holding and defines the near-term floor.
Sentiment & News
Key News Insights: ⢠Beat-and-raise quarter ⢠Stelara pressure ⢠Pipeline confidence Johnson & Johnson delivered a beat-and-raise Q1 with strong drug and MedTech performance, but Stelara erosion, patent pressure, and valuation concerns keep upside measured.
AI Summary
JNJ is no longer a simple defensive compounder; with Stelara's patent cliff, litigation overhangs, and a premium valuation already priced in, the stock now hinges on execution across new pharma/medtech growth drivers and sustaining cash flow and margins through the transition.
Description
Johnson & Johnson develops, manufactures and sells healthcare products worldwide through three principal businesses: Consumer Health, Pharmaceuticals and MedTech. Its Consumer Health unit offers household personal-care and over-the-counter medicines, the Pharmaceuticals division markets prescription therapies across immunology, infectious disease, CNS, oncology, cardiovascular and metabolic indications, and the MedTech business supplies devices for cardiovascular, neurovascular, orthopaedic, surgical and vision care. The company distributes to retailers, wholesalers, hospitals and healthcare professionals and is headquartered in New Brunswick, New Jersey; it was founded in 1886.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 23 | Jan 30 | JNJ | Johnson & Johnson | Johnson & Johnson offers robust near-term return potential backed by strong Q4 2025 results, significant FDA approvals and pipeline catalysts, plus positive short-term technical momentum supporting a bullish outlook into early 2026. | Closed | +3.2% |
| Nov 17 | Nov 24 | JNJ | Johnson & Johnson | Strong Q3 2025 beat with raised guidance, multiple near-term FDA approvals boosting revenue prospects, strategic M&A enhancing growth, robust free cash flow, and positive technical momentum just below the upper Bollinger band support a favorable near-term price appreciation setup. | Closed | +3.2% |